Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

CG-750

Alternative Names: cg-750, cg750, cg 750, cg200750
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

CG-750 is a drug used to treat patients with Fibrotic diseases including non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), chronic kidney diseases (CKD), Alport Syndrome, etc. (Sourced from: http://www.crystalgenomics.com/en/m21_4.php?subPipeCate=1#main)

Mechanisms of Action: HDAC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: CrystalGenomics
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CG200750-1-01

P1

Completed

Healthy Volunteers

2020-09-18

28%

Recent News Events

Date

Type

Title

04/01/2024

PubMed

 Pharmacokinetics, pharmacodynamics and safety of oral formulation (CG-750) of ivaltinostat, a histone deacetylase inhibitor, compared to IV formulation (CG-745).

03/09/2021

PubMed

 Changes of Mineralogical Properties and Biological Activities of Gypsum and Its Calcined Products with Different Phase Structures.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions